27894149|t|2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-Glucoside Attenuates Ischemia / Reperfusion-Induced Brain Injury in Rats by Promoting Angiogenesis
27894149|a|cerebral ischemia can cause brain infarcts, which are difficult to recover due to poor angiogenesis. 2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-glucoside is a natural polyphenol, has antioxidant and anti-inflammatory activity, and can protect from ischemic neuronal injury. However, little is known about the effect of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside on brain microcirculation after stroke. This study aimed at investigating the influence of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside on brain lesions and angiogenesis after stroke. Sprague-Dawley rats were subjected to right middle cerebral artery occlusion and treated with vehicle, nimodipine, or different doses of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside daily beginning at 6 h post-middle cerebral artery occlusion for 14 days. The volume of cerebral infarcts, degree of neurological dysfunction, and level of microvessel density were determined longitudinally. The levels of vascular endothelial growth factor, angiopoietin 1, and angiopoietin receptor-2 expression in the brain lesions were characterized by immunohistochemistry and Western blot assays at 14 days post-middle cerebral artery occlusion. We found that 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside significantly promoted postoperative recovery in rats by minimizing the volume of cerebral infarcts and improving neurological dysfunction in a dose - and time-dependent manner. Additionally, 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside significantly increased the microvessel density in the brain and upregulated CD31 expression in ischemic penumbra, relative to that in the control. Finally, treatment with 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside significantly upregulated the relative levels of vascular endothelial growth factor, angiopoietin 1, and angiopoietin receptor-2 expression in the brain lesions of rats. Therefore, these data indicated that 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside treatment promoted angiogenesis and recovery from ischemia/reperfusion -induced brain injury in rats.
27894149	0	47	2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-Glucoside	T109,T121	C0964606
27894149	48	58	Attenuates	T052	C0599946
27894149	59	67	Ischemia	T046	C0022116
27894149	70	89	Reperfusion-Induced	T037	C0035126
27894149	90	102	Brain Injury	T037	C0270611
27894149	106	110	Rats	T015	C0034721
27894149	114	123	Promoting	T052	C0033414
27894149	124	136	Angiogenesis	T042	C0302600
27894149	137	154	cerebral ischemia	T047	C0917798
27894149	165	179	brain infarcts	T047	C0521542
27894149	219	236	poor angiogenesis	T042	C0302600
27894149	238	285	2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-glucoside	T109,T121	C0964606
27894149	291	309	natural polyphenol	T109,T121	C0071649
27894149	315	326	antioxidant	T044	C1148564
27894149	331	348	anti-inflammatory	T121	C0003209
27894149	349	357	activity	T052	C0441655
27894149	380	388	ischemic	T046	C0022116
27894149	389	404	neuronal injury	T037	C0161479
27894149	441	447	effect	T080	C1280500
27894149	451	498	2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	T109,T121	C0964606
27894149	502	507	brain	T023	C0006104
27894149	508	524	microcirculation	T042	C0025962
27894149	531	537	stroke	T047	C0038454
27894149	544	549	study	T062	C2603343
27894149	559	572	investigating	T169	C1292732
27894149	590	637	2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	T109,T121	C0964606
27894149	641	654	brain lesions	T047	C0221505
27894149	659	671	angiogenesis	T042	C0302600
27894149	678	684	stroke	T047	C0038454
27894149	686	705	Sprague-Dawley rats	T015	C0034715
27894149	724	762	right middle cerebral artery occlusion	T020	C0740391
27894149	767	779	treated with	T061	C0332293
27894149	789	799	nimodipine	T109,T121	C0028094
27894149	814	819	doses	T081	C0178602
27894149	823	870	2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	T109,T121	C0964606
27894149	894	931	post-middle cerebral artery occlusion	T020	C0740391
27894149	959	976	cerebral infarcts	T047	C0007785
27894149	988	1012	neurological dysfunction	T033	C1709219
27894149	1027	1038	microvessel	T023	C2350570
27894149	1039	1046	density	T081	C0178587
27894149	1093	1127	vascular endothelial growth factor	T116,T123	C1256770
27894149	1129	1172	angiopoietin 1, and angiopoietin receptor-2	T116,T192	C3853567
27894149	1173	1183	expression	T045	C0597360
27894149	1191	1204	brain lesions	T047	C0221505
27894149	1210	1223	characterized	T052	C1880022
27894149	1227	1247	immunohistochemistry	T060	C0021044
27894149	1252	1271	Western blot assays	T059	C0949466
27894149	1283	1320	post-middle cerebral artery occlusion	T020	C0740391
27894149	1336	1383	2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	T109,T121	C0964606
27894149	1398	1406	promoted	T052	C0033414
27894149	1407	1429	postoperative recovery	T033	C4304804
27894149	1433	1437	rats	T015	C0034721
27894149	1466	1483	cerebral infarcts	T047	C0007785
27894149	1498	1522	neurological dysfunction	T033	C1709219
27894149	1528	1532	dose	T081	C0178602
27894149	1576	1623	2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	T109,T121	C0964606
27894149	1624	1647	significantly increased	T081	C4055637
27894149	1652	1663	microvessel	T023	C2350570
27894149	1664	1671	density	T081	C0178587
27894149	1679	1684	brain	T023	C0006104
27894149	1689	1700	upregulated	T044	C0041904
27894149	1701	1705	CD31	T116,T129	C0081939
27894149	1706	1716	expression	T045	C1171362
27894149	1720	1728	ischemic	T046	C0022116
27894149	1729	1737	penumbra	T082	C1254362
27894149	1781	1795	treatment with	T061	C0332293
27894149	1796	1843	2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	T109,T121	C0964606
27894149	1858	1869	upregulated	T044	C0041904
27894149	1893	1927	vascular endothelial growth factor	T116,T123	C1256770
27894149	1929	1972	angiopoietin 1, and angiopoietin receptor-2	T116,T192	C3853567
27894149	1973	1983	expression	T045	C0597360
27894149	1991	2004	brain lesions	T047	C0221505
27894149	2008	2012	rats	T015	C0034721
27894149	2031	2035	data	T078	C1511726
27894149	2036	2045	indicated	T033	C1444656
27894149	2051	2098	2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside	T109,T121	C0964606
27894149	2099	2108	treatment	T061	C0332293
27894149	2109	2117	promoted	T052	C0033414
27894149	2118	2130	angiogenesis	T042	C0302600
27894149	2149	2169	ischemia/reperfusion	T037	C0035126
27894149	2179	2191	brain injury	T037	C0270611
27894149	2195	2199	rats	T015	C0034721